Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | EHD1 | Q9H4M9 | 5/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.36 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067292 | 0.93 | SLC6A3 (0.49) | SLC6A3ELANEEHD1GABBR2GABBR1 | |
| SCHEMBL19432907 | 0.73 | SLC6A3 (0.65) | SLC6A3ELANEGABBR2GABBR1KRAS | |
| SCHEMBL19231271 | 0.70 | SLC6A3 (0.66) | SLC6A3ELANEGABBR2GABBR1F11 | |
| SCHEMBL19231498 | 0.69 | SLC6A3 (0.67) | SLC6A3GABBR2GABBR1F11KRAS | |
| Linaclotide SCHEMBL24484183 | 0.67 | SLC6A3 (1.00) | SLC6A3ELANECHRNA10CHRNA9KLK5 | |
| Linaclotide SCHEMBL13114620 | 0.67 | SLC6A3 (1.00) | SLC6A3ELANECHRNA10CHRNA9KLK5 | |
| Linaclotide SCHEMBL25681390 | 0.67 | SLC6A3 (1.00) | SLC6A3ELANECHRNA10CHRNA9KLK5 | |
| Linaclotide SCHEMBL25842727 | 0.67 | SLC6A3 (1.00) | SLC6A3ELANECHRNA10CHRNA9KLK5 | |
| SCHEMBL24484001 | 0.66 | SLC6A3 (0.89) | SLC6A3ELANECHRNA10CHRNA9CHRNA7 | |
| Linaclotide SCHEMBL25382574 | 0.66 | SLC6A3 (0.98) | SLC6A3ELANEGABBR2GABBR1CHRNA10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272007-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272007-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | GRPR, GIPR, GCGR | SLC6A3 3933/4885ELANE 1868/4885EHD1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.